S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
1970’s computer coder issues shocking A.I. warning (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
[Urgent!] Generational Wealth Gameplan (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Options trading has suddenly become more reliable. (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
1970’s computer coder issues shocking A.I. warning (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
[Urgent!] Generational Wealth Gameplan (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Options trading has suddenly become more reliable. (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
1970’s computer coder issues shocking A.I. warning (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
[Urgent!] Generational Wealth Gameplan (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Options trading has suddenly become more reliable. (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
1970’s computer coder issues shocking A.I. warning (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
[Urgent!] Generational Wealth Gameplan (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Options trading has suddenly become more reliable. (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:CYAD

Celyad Oncology (CYAD) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free CYAD Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.40
▼
$0.65
50-Day Range
$0.59
▼
$0.85
52-Week Range
$0.46
▼
$3.07
Volume
3,009 shs
Average Volume
N/A
Market Capitalization
$15.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisHeadlinesSocial Media
CYAD stock logo

About Celyad Oncology Stock (NASDAQ:CYAD)

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

CYAD Stock News Headlines

April 4, 2024 | finance.yahoo.com
Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights
March 29, 2024 | seekingalpha.com
CSBR Champions Oncology, Inc.
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
January 17, 2024 | finanznachrichten.de
Celyad Oncology SA: Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
January 16, 2024 | finance.yahoo.com
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
December 17, 2023 | businesswire.com
Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
December 4, 2023 | finance.yahoo.com
Celyad Announces Management Change
November 14, 2023 | tmcnet.com
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
November 11, 2023 | lse.co.uk
Celyad Oncology Share Price (CYAD.BR)
November 9, 2023 | finanznachrichten.de
Celyad Oncology SA: Celyad Oncology reports third quarter 2023 financial results and recent business highlights
November 9, 2023 | finance.yahoo.com
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
September 26, 2023 | finanznachrichten.de
Celyad Oncology SA: Celyad Oncology announces the termination of its American Depository Receipt program
September 25, 2023 | marketwatch.com
Celyad Oncology to Terminate ADR Program
September 25, 2023 | finance.yahoo.com
Celyad Oncology announces the termination of its American Depository Receipt program
September 15, 2023 | finance.yahoo.com
Celyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLC
September 12, 2023 | businesswire.com
Celyad Oncology SA: Publication of a Transparency Notification Received from Tolefi SA
September 12, 2023 | ca.finance.yahoo.com
Celyad Oncology SA (CYAD.BR)
September 7, 2023 | finance.yahoo.com
Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC
September 4, 2023 | finanznachrichten.de
Celyad Oncology SA: Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
September 4, 2023 | finance.yahoo.com
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
September 4, 2023 | investing.com
Celyad Oncology (CYADY) Earnings Dates & Reports
August 29, 2023 | finance.yahoo.com
Celyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments From Historical Shareholders
August 25, 2023 | finanznachrichten.de
Celyad Oncology SA: Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
July 19, 2023 | investing.com
Celyad Oncology SA (CYADY)
May 16, 2023 | finanznachrichten.de
Celyad Oncology SA: Celyad Oncology announces receipt of Nasdaq delisting notice
May 15, 2023 | finance.yahoo.com
Celyad Oncology Announces Receipt of Nasdaq Delisting Notice
See More Headlines
Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYAD
CUSIP
N/A
CIK
1637890
Web
www.celyad.com
Phone
(210) 039-4100
Fax
321-039-4141
Employees
95
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$110,000.00
Price / Sales
144.65
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.20 per share
Price / Book
3.00

Miscellaneous

Outstanding Shares
26,520,000
Free Float
26,276,000
Market Cap
$15.91 million
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Georges Rawadi
    Chief Executive Officer & Executive Director
  • David Georges
    Vice President-Finance & Administration
  • Eytan Breman
    Director-Research & Development
  • An Phan
    Head-Legal

Key Competitors

View All Competitors

CYAD Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Celyad Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX).

When did Celyad Oncology IPO?

Celyad Oncology (CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

This page (NASDAQ:CYAD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
The Next Nvidia?
InvestorPlace
How Biden has already won 2024
Porter & Company
Options trading has suddenly become more reliable.
Eagle Publishing
1970’s computer coder issues shocking A.I. warning
TradeSmith